Comprehensive analyses of flow cytometry and immunohistochemistry results revealed that bevacizumab treatment enhanced the HIF-1α expression and increased the proportion of CD44+/CD117+ cells, resulting in the tumor recurrence in both the bevacizumab alone and bevacizumab + cisplatin groups. The gene discussed is HIF1A; the disease is neoplasm.